Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Hong Yan

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Lung Cancer (Amsterdam, Netherlands)|November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) studyJian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2026
LAMPAD:An Integrated ctDNA-Based Model for Predicting Potential Cure in Resected NSCLC PatientsJia-Tao Zhang, Ke-Zhong Chen, Xuan Gao, et al.
Cancer Cell|October 10, 2023
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patientsYi Pan, Jia-Tao Zhang, Xuan Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
Nature Medicine|February 27, 2025
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastasesMei-Mei Zheng, Qing Zhou, Hua-Jun Chen, et al.
Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Lung Cancer (Amsterdam, Netherlands)|November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) studyJian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2026
LAMPAD:An Integrated ctDNA-Based Model for Predicting Potential Cure in Resected NSCLC PatientsJia-Tao Zhang, Ke-Zhong Chen, Xuan Gao, et al.
Cancer Cell|October 10, 2023
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patientsYi Pan, Jia-Tao Zhang, Xuan Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Nature Medicine|July 24, 2023
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSi-Yang Maggie Liu, Hai-Yan Tu, Xue-Wu Wei, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastasesYang-Si Li, Wenpu Lai, Kai Yin, et al.
Nature Medicine|February 27, 2025
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastasesMei-Mei Zheng, Qing Zhou, Hua-Jun Chen, et al.
Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.
Pageof 12